471 related articles for article (PubMed ID: 1131824)
1. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
[TBL] [Abstract][Full Text] [Related]
2. Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
Griswold DP; Dykes DJ; Kelley CA; Roberts BJ; Dominick CA
Cancer Chemother Rep 2; 1974 Mar; 4(1):99-108. PubMed ID: 4524043
[No Abstract] [Full Text] [Related]
3. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
4. Combinations of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors.
Bernacki RJ; Bansal SK; Gurtoo HL
Cancer Res; 1987 Feb; 47(3):799-802. PubMed ID: 3100025
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of combined action of vitamins A, E and C and cyclophosphane or adriamycin on growth of transplanted tumors in mice].
Mosienko VS; Khasanova LT; Sukolinskiĭ VN; Morozkina TS
Eksp Onkol; 1990; 12(3):55-7. PubMed ID: 2344827
[TBL] [Abstract][Full Text] [Related]
7. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
9. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635
[TBL] [Abstract][Full Text] [Related]
10. Exploratory studies of vitamin A and cyclophosphamide in tumor-bearing mice.
Nathanson L; Maddock CL; Hall TC
J Clin Pharmacol J New Drugs; 1969; 9(6):359-73. PubMed ID: 5260199
[No Abstract] [Full Text] [Related]
11. L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
Zaharko D; Plowman J; Waud W; Dykes D; Malspeis L
Cancer Res; 1992 Jul; 52(13):3604-9. PubMed ID: 1617631
[TBL] [Abstract][Full Text] [Related]
12. Effects of cimetidine combination with cyclophosphamide in transplanted murine tumors.
Khandalekar DD; Ganu UK; Gokhale SV
Indian J Physiol Pharmacol; 1989; 33(3):171-4. PubMed ID: 2592043
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of cell kinetic changes after cyclophosphamide treatment in "spontaneous" and "transplantable" mammary tumors.
Branunschweiger PG; Schiffer LM
Cancer Treat Rep; 1978 May; 62(5):727-36. PubMed ID: 657158
[TBL] [Abstract][Full Text] [Related]
14. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Ninomiya K; Sekido S; Araki T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. I. Acute toxicity and antitumor activity in mouse transplantable tumor systems.
Matuszyk J; Kuśnierczyk H; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):77-88. PubMed ID: 2619512
[TBL] [Abstract][Full Text] [Related]
16. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW; Biro TG
Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
[TBL] [Abstract][Full Text] [Related]
17. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
18. Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosphamide and irradiation with 10 MeV electrons--verification of the therapeutic results with 31P-NMR spectroscopy.
Ulmer W
Strahlenther Onkol; 1991 Sep; 167(9):553-60. PubMed ID: 1925940
[TBL] [Abstract][Full Text] [Related]
19. Experimental approach for the search of effective drug combination in cancer chemotherapy.
Bello JL; Kariev NI; Mainardi JV; Betancourt M; Lage A; Barroso MC; Alfonso L
Neoplasma; 1982; 29(1):65-71. PubMed ID: 7070556
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
